Search results
Showing 346 to 360 of 878 results for score
Total distal radioulnar joint replacement for symptomatic joint instability or arthritis (HTG451)
Evidence-based recommendations on total distal radioulnar joint replacement for symptomatic joint instability or arthritis in adults. This involves removing the wrist end of the ulna and replacing it with a metal prosthesis that also attaches to the wrist end of the radius.
Laparoscopic augmentation cystoplasty (including clam cystoplasty) (HTG207)
Evidence-based recommendations on Laparoscopic augmentation cystoplasty (including clam cystoplasty). This involves sewing or stapling a tissue graft from a section of the small intestine (ileum), colon or other substitutes to the urinary bladder.
View recommendations for HTG207Show all sections
Sections for HTG207
EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)
NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration
Evidence-based recommendations on dupilumab (Dupixent) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.
This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease).
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.
View recommendations for TA199Show all sections
NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .
This indicator covers the percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM81
Evidence-based recommendations on implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes. This involves inserting an artificial cornea surrounded by a corneal graft from a human donor.
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults.
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .
Ticagrelor for the treatment of acute coronary syndromes (TA236)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)
Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.
Coil embolisation of ruptured intracranial aneurysms (HTG64)
Evidence-based recommendations on coil embolisation of ruptured intracranial aneurysms. This involves passing a thin tube through the body to place coils inside the aneurysm.
View recommendations for HTG64Show all sections
Sections for HTG64
Evidence-based recommendations on ataluren (Translarna) for Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk.